Findings

What do systematic reviews say?

265 questions · 283 findings · 18 reviews · Skin

No studies found 59 · 20.8%GRADE not reported 20 · 7.1%Very low 45 · 15.9%Low 58 · 20.5%Moderate 64 · 22.6%High 37 · 13.1%

Overall survival† · people with cutaneous melanoma

Anti‐PD1 monoclonal antibodies leads to lower overall survival† compared with anti‐CTLA4 monoclonal antibodies (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.63 [0.6, 0.66]
764 participants
High

Progression‐free survival · people with cutaneous melanoma

Anti‐PD1 monoclonal antibodies leads to lower progression‐free survival† compared with anti‐CTLA4 monoclonal antibodies (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.54 [0.5, 0.6]
1465 participants
High

Tumour response · people with cutaneous melanoma

Anti‐PD1 monoclonal antibodies leads to higher tumour response compared with anti‐CTLA4 monoclonal antibodies (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 2.47 [2.01, 3.04]
1465 participants
High

Toxicity (≥ G3) · people with cutaneous melanoma

Anti‐PD1 monoclonal antibodies may leads to lower toxicity (≥ G3) compared with anti‐CTLA4 monoclonal antibodies (low certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 0.7 [0.54, 0.91]
1465 participants
Low

Overall survival† · people with cutaneous melanoma

Anti‐CTLA4 monoclonal antibodies plus chemotherapy showed no clear difference in overall survival† compared with chemotherapy (low certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.81 [0.65, 1.01]
1157 participants
Low